// App-Quantinova.ai

TPS619 : ARB: Phase II window of opportunity study of short-term preoperative treatment with enzalutamide in ER-positive and triple-negative breast cancer.

Researchers

Presenter

  • Peter Schmid

Principal Investigators

  • Duncan A Wheatley

  • Alastair Mark Thompson

  • Pankaj Roy

  • Nigel J Bundred

  • Anand David Purushotham

  • Stuart McINTOSH

  • Sherko Kummel

  • Nadia Harbeck

  • Ulrike Nitz

  • David Barnes

  • Shah-Jalal Sarker

  • Kelly Mousa

  • Javier Cortes

Medical Centers

  • Bart's Cancer Institute, London, United Kingdom

  • Royal Cornwall Hospital, Truro, United Kingdom

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Churchill Hospital, Oxford, United Kingdom

  • University of Manchester, Manchester, United Kingdom

  • Guy's Hospital, London, United Kingdom

  • Belfast City Hospital, Belfast, United Kingdom

  • Breast Unit, Kliniken Essen-Mitte, Essen, Germany

  • Brustzentrum der Universitat Munchen (LMU), Munich, Germany

  • Evangelic Hospital Bethesda, Moenchengladbach, Germany

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

Locations

  • United States

  • Germany

  • United Kingdom

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

Biomarkers

  • Proliferation marker protein Ki-67

Drug/Treatment

  • Enzalutamide

  • Exemestane

Outcome

  • N/A

Study Design

  • Randomized

  • Multinational

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved